Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Content from MarketBeat
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?Author: Jeffrey Neal Johnson. Published: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
In investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance notable.
Is Elon about to trigger another 315X opportunity?
Elon gave Tesla investors the chance to make more than 315 times their money when he revived the electric vehicle industry. $1 billion fund manager Louis Navellier believes Elon's "Project Apex" will mint a new generation of millionaires. Click here to get the details.
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the last trading days of March. The sharp downturn has prompted questions about whether the foundation of this industry leader is eroding or if a value opportunity has emerged for long-term investors. A closer look suggests a disconnect between short-term market sentiment and Abbott’s operational reality. Separating the Signal From the NoiseThe stock’s decline reflects two distinct pressures. The first is an internal headwind from its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in this division, driven largely by U.S. pediatric market-share losses and pricing dynamics that constrained volume. Management has acknowledged the issue and laid out a clear turnaround plan. CEO Robert B. Ford described price and promotion initiatives and a pipeline of at least eight new product launches in 2026, forecasting a return to growth in the second half of the year. The second factor is broader and external: a rotation of capital in the market. During periods of economic optimism, investors often shift funds away from defensive sectors like the healthcare sector into higher-beta areas such as artificial intelligence (AI) and the energy sector in search of faster returns. That trend has weighed on many fundamentally sound healthcare names, including Abbott, for reasons largely unrelated to each company’s underlying performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition navigates a short-term recovery, Abbott’s core remains robust, led by its largest and most profitable division: Medical Devices. That segment is accelerating, posting 10.4% organic growth in the most recent quarter. Abbott’s diversified model helps offset the isolated weakness in Nutrition, and the company’s overall health is most apparent in these high-performing areas.
Medical Devices: The Medical Devices business is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a major growth driver. This product line, which lets users track glucose without routine fingersticks, generated more than $7.5 billion in sales in 2025 and remains central to Abbott’s sustained success. Cardiovascular Leadership: Abbott is a dominant force in cardiovascular care. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. That performance stems from a portfolio of best-in-class products—such as MitraClip and TriClip—and a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning for future growth through the acquisition of Exact Sciences. Exact Sciences is a leader in cancer screening and diagnostics, best known for its non-invasive colon cancer test, Cologuard. The deal would immediately add a high-growth vertical in cancer diagnostics to Abbott’s portfolio, expanding its presence in a multi-billion-dollar market and creating a meaningful new revenue stream over time. Wall Street appears to share the bullish view. Analysts maintain a Moderate Buy consensus rating on the stock, with an average 12-month price target of $135.47—implying more than 30% upside from current levels and suggesting the stock may be undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on income, Abbott’s dividend is a central attraction. Abbott is a member of the S&P 500 Dividend Kings, a group of companies that have increased their dividends for at least 50 consecutive years. That track record reflects a deep commitment to returning capital to shareholders through all market cycles. The recent drop in Abbott’s stock price benefits new investors by boosting the dividend yield to roughly 2.5% at current prices, allowing investors to lock in a higher income rate from a historically reliable payer. The dividend’s payout ratio is about 68% of earnings and represents only about 37% of cash flow, indicating Abbott generates ample cash to cover the dividend with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from its business fundamentals. Temporary headwinds in a single division and a broader market rotation have depressed the stock price, yet Abbott’s fundamental growth engines are accelerating. Its dominant Medical Devices division continues to deliver strong results, the dividend remains a bedrock of reliability, and strategic moves like the Exact Sciences acquisition add meaningful upside. For investors with a long-term horizon, the current valuation highlights a gap between price and intrinsic value that merits consideration. |
